The disclosure provides cysteamine salt and cystamine formulations comprising enteric coatings. The disclosure also provides composition for use in treating diseases and disorders that can be treated with cysteamine.

Formulations comprising cycloserine compounds and one or more enteric materials in a solid dosage form, and uses thereof for treating and/or reducing the risk of a neuropsychiatric disorder or tuberculosis.

Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.

The present invention is directed film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain a water-soluble polymer, an opacifying agent such as, calcium carbonate or starch, and isomalt. The film coating compositions can be in the form of a fully formulated dry blend or as an aqueous suspension which can be applied either directly to a substrate or after the substrate has been coated with a subcoat. Oral substrates such as tablets coated with the film coating compositions are also disclosed and have high opacity and overall excellent appearance.

Described herein is a fibrous water-soluble unit dose with an active agent in the form of an acid.

The embodiments disclose a method including using a sonication process to encapsulate a human consumable substance within a liposome vesicle, continuously cooling the liposome vesicle and the encapsulated human consumable substance to a predetermined temperature during the sonication process, adding starch and essential oils to the cooled liposome vesicle and the encapsulated human consumable substance to create a mixture, using at least one analytical test for checking predetermined quality control standards of the encapsulated human consumable ingredients, mixtures and finished products, and using at least one delivery form for the mixture suitable human consumption.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

The present invention discloses an immediate release tablet comprising at least a tablet core, wherein the tablet core comprises at most 20% brexpiprazole relative to the total of the tablet core, and at least one pharmaceutically acceptable excipient, wherein the tablet core is made by direct compression. Also disclosed are a batch of such immediate release tablets, and a process for preparing such immediate release tablets.

The present invention relates to a composition which comprises a mixture which comprises or, alternatively, consists of an extract (a) of a fruit of at least one plant of the genus Vaccinium and at least one ingredient (b) acceptable for pharmaceutical or food use and the use thereof in the prevention and/or treatment of diverticular disease or of a pathology deriving therefrom or correlated thereto.

In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example, cholestasis and/or cholestatic pruritus.